Core Insights - Johnson & Johnson (JNJ) is a leading global healthcare company with a strong market presence, set to release quarterly earnings on October 14, 2025, with an estimated EPS of $2.78 and projected revenue of approximately $23.7 billion [1][6] Financial Performance - Goldman Sachs anticipates continued strong performance from JNJ, with the stock increasing by 31% this year, significantly outperforming the S&P 500's 14% rise [2][6] - JNJ has a history of outperforming earnings estimates, with an average earnings surprise of 5.96% over the last two quarters [3][6] - In the most recent quarter, JNJ reported earnings of $2.66 per share, surpassing the anticipated $2.77 per share, resulting in a 4.14% surprise [3] Financial Metrics - JNJ has a price-to-earnings (P/E) ratio of approximately 20.25, a price-to-sales ratio of about 5.04, and an enterprise value to sales ratio of around 5.40 [4] - The enterprise value to operating cash flow ratio is approximately 21.24, indicating the company's valuation in relation to its cash flow from operations [4] - The earnings yield is about 4.94%, and the debt-to-equity ratio is approximately 0.65, suggesting a balanced use of debt and equity [5]

Core Insights - Nasdaq, Inc. (NDAQ) is a diversified financial services and technology company with a market cap of $50.6 billion, operating multiple stock exchanges globally [1] Earnings Expectations - NDAQ is set to report Q3 earnings on October 21, with analysts predicting a profit of $0.82 per share, reflecting a 10.8% increase from $0.74 per share in the same quarter last year [2] - For the current fiscal year, analysts expect an EPS of $3.33, which is an 18.1% increase from $2.82 in fiscal 2024, with further growth anticipated to $3.69 in FY 2026 [3] Stock Performance - NDAQ stock has increased by 22.3% over the past 52 weeks, outperforming the Financial Select Sector SPDR Fund's 17.6% and the S&P 500 Index's 17.2% during the same period [4] - Following the release of Q2 results, NDAQ's stock rose by 5.9%, with net revenues reported at $1.3 billion, a 12.7% year-over-year increase, and non-GAAP net earnings up 23.9% to $492 million [5] Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for NDAQ, with 13 out of 21 analysts recommending "Strong Buy," three suggesting "Moderate Buy," and five advising "Hold" [6] - The mean price target for NDAQ is $103.61, indicating a potential 17.5% upside from the current market price [6]

Core Insights - West Pharmaceutical Services, Inc. (WST) is a leading manufacturer of containment and delivery systems for injectable drugs, with a market cap of $19.6 billion [1] - The company is expected to announce its fiscal third-quarter earnings for 2025 soon, with analysts predicting a profit of $1.67 per share, a decrease of 9.7% from the previous year [2] Financial Performance - For the full year, analysts anticipate WST to report an EPS of $6.74, slightly down from $6.75 in fiscal 2024, but expect a rise of 11.7% year-over-year to $7.53 in fiscal 2026 [3] - In Q2, WST reported an adjusted EPS of $1.84, surpassing Wall Street expectations of $1.51, with revenue of $766.5 million exceeding forecasts of $727.3 million [6] Stock Performance - WST stock has underperformed the S&P 500 Index, which gained 17.2% over the past 52 weeks, with WST shares down 9.6% during the same period [4] - The stock also underperformed the Health Care Select Sector SPDR Fund, which saw a 5% dip [4] Analyst Ratings - Analysts maintain a bullish consensus on WST stock, with a "Strong Buy" rating from 11 out of 15 analysts, one suggesting a "Moderate Buy," and three giving a "Hold" [7] - The average analyst price target for WST is $320.50, indicating a potential upside of 19.6% from current levels [7] Challenges and Risks - WST's underperformance is attributed to factors such as short-term ordering volatility, competitive pricing pressure, and macroeconomic challenges like fluctuating raw material costs [5] - Regulatory timelines and evolving quality standards present execution risks, while normalizing demand for pandemic-related products may affect year-over-year comparisons [5]

Core Viewpoint - Omnicom Group Inc. is set to announce its fiscal third-quarter earnings for 2025, with analysts expecting a profit increase, despite the company's stock underperforming compared to major indices over the past year [1][2][4]. Financial Performance - Analysts anticipate Omnicom to report earnings per share (EPS) of $2.15 for the third quarter, reflecting a 5.9% increase from $2.03 in the same quarter last year [2]. - For the full fiscal year 2025, EPS is projected to be $8.48, up 5.2% from $8.06 in fiscal 2024, with further growth expected to $9.10 in fiscal 2026, representing a 7.3% year-over-year increase [3]. Stock Performance - Over the past 52 weeks, Omnicom's stock has declined by 24.7%, significantly underperforming the S&P 500 Index, which gained 17.6%, and the Communication Services Select Sector SPDR ETF, which rose by 29.1% [4]. Analyst Ratings - The consensus among analysts is moderately bullish, with a "Moderate Buy" rating overall. Out of 11 analysts, five recommend a "Strong Buy" and six suggest a "Hold" [6]. - The average price target for Omnicom's stock is $93.62, indicating a potential upside of 21.8% from current levels [6].

Company Overview - Philip Morris International Inc. (PM) has a market capitalization of $250.4 billion and operates in over 180 countries, primarily known for its cigarette and smoke-free product brands, including Marlboro, the top-selling international cigarette brand [1] Earnings Expectations - The company is set to announce its fiscal Q3 2025 earnings results on October 21, with analysts predicting an adjusted EPS of $2.11, reflecting a 10.5% increase from $1.91 in the same quarter last year [2] - For fiscal 2025, the expected adjusted EPS is $7.52, which represents a 14.5% increase from $6.57 in fiscal 2024 [3] Stock Performance - Over the past 52 weeks, shares of Philip Morris have increased by 32%, outperforming the S&P 500 Index's rise of 17.6% and the Consumer Staples Select Sector SPDR Fund's decline of 5% [4] - Following the Q2 earnings release on July 22, shares dropped by 8.4%, despite reporting a net revenue of $10.1 billion, which grew by 7.1% year-over-year, and an adjusted EPS of $1.91, surpassing analyst estimates of $1.85 with a year-over-year increase of 20.1% [5] Analyst Ratings - The consensus view among analysts is cautiously optimistic, with a "Moderate Buy" rating overall. Out of 15 analysts, nine recommend "Strong Buy," two suggest "Moderate Buy," and four advise "Hold" [6] - The average analyst price target for Philip Morris is $193.77, indicating a potential upside of 22.7% from current market prices [6]

Denver, Colorado-based Newmont Corporation (NEM) is a mining company. It produces and explores gold, copper, silver, zinc, and lead with a primary focus on gold. With a market cap of $94.4 billion, Newmont’s operations span the Americas, Caribbean, Africa, and the Indo-Pacific. The mining giant is gearing up to announce its third-quarter results after the markets close on Thursday, Oct. 23. Ahead of the event, analysts expect Newmont to report a profit of $1.27 per share, up 56.8% from $0.81 per share rep ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

New York-based BlackRock, Inc. (BLK) is one of the world’s largest asset management firms. It provides various investment and technology services to institutional and retail clients. With a market cap of $174.7 billion, BlackRock’s operations span various countries in the Americas, Europe, the Indo-Pacific, Africa, and internationally. The asset management giant is expected to report its third-quarter results before the markets open on Friday, Oct. 10. Ahead of the event, analysts expect BLK to deliver an ...

Core Viewpoint - Carnival Corporation & plc is preparing to release its quarterly earnings on September 29, 2025, with analysts estimating an EPS of $1.31 and projected revenue of approximately $8.09 billion [1][6] Financial Performance - Carnival's stock has surged about 216% over the past three years but remains 57% below its all-time highs from 2018, primarily due to managing a substantial debt of $27 billion [2][6] - The company has a price-to-earnings (P/E) ratio of approximately 15.96 and a price-to-sales ratio of about 1.53, indicating the market's valuation of its sales [3][6] - The enterprise value to sales ratio stands at around 2.55, while the enterprise value to operating cash flow ratio is approximately 12.21, reflecting cash flow efficiency [3] Financial Ratios - Carnival's debt-to-equity ratio is approximately 2.86, highlighting its financial leverage, and a current ratio of around 0.34 indicates its ability to cover short-term liabilities [4] - The company's earnings yield is about 6.27%, providing insight into the return on investment [4] Market Outlook - The upcoming earnings report is crucial, as a positive surprise could boost the stock price, while a shortfall might lead to a decline [4] - Management's discussion during the earnings call will be vital for assessing the sustainability of price changes and future earnings projections [5] - Declining interest rates may alleviate some concerns regarding high debt levels, but the key question remains whether demand for Carnival's services will persist long enough to reduce its debt [5]

Company Overview - Trinity Asset Management was founded by Brian Gilmartin in May 1995, focusing on providing attention and service to individual investors and institutions that were underserved by larger firms [1] - Brian Gilmartin has a background as a fixed-income/credit analyst and has experience working with a Chicago broker-dealer and Stein Roe & Farnham before establishing his own firm [1] Educational Background - Brian Gilmartin holds a BSBA in Finance from Xavier University, Cincinnati, Ohio, obtained in 1982, and an MBA in Finance from Loyola University, Chicago, completed in January 1985 [1] - He earned the CFA designation in 1994 [1] Professional Experience - Brian Gilmartin has contributed to financial writing for various platforms, including TheStreet.com from 2000 to 2012 and WallStreet AllStars from August 2011 to Spring 2012 [1] - He has also written for Minyanville.com and has been quoted in numerous publications, including the Wall Street Journal [1]